(Q35233470)

English

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

0 references

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation (English)

1 reference

Europe PubMed Central

7 August 2017

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Yosuke Togashi

1

1 reference

Europe PubMed Central

7 August 2017

Katsuhiro Masago

2

1 reference

Europe PubMed Central

7 August 2017

Masahide Fukudo

3

1 reference

Europe PubMed Central

7 August 2017

Yasuhiro Tsuchido

4

1 reference

Europe PubMed Central

7 August 2017

Chiyuki Okuda

5

1 reference

Europe PubMed Central

7 August 2017

Young Hak Kim

6

1 reference

Europe PubMed Central

7 August 2017

Yasuaki Ikemi

7

1 reference

Europe PubMed Central

7 August 2017

Yuichi Sakamori

8

1 reference

Europe PubMed Central

7 August 2017

Tadashi Mio

9

1 reference

Europe PubMed Central

7 August 2017

Toshiya Katsura

10

1 reference

Europe PubMed Central

7 August 2017

Michiaki Mishima

11

1 reference

Europe PubMed Central

7 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 June 2011

1 reference

Europe PubMed Central

7 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

7 August 2017

68

1 reference

Europe PubMed Central

7 August 2017

4

1 reference

Europe PubMed Central

7 August 2017

1089-1092

1 reference

Europe PubMed Central

7 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-011-1691-z

0 references

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

13 July 2018

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180562

26 September 2018

A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1691-Z

21 January 2018

Identifiers

10.1007/S00280-011-1691-Z

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35233470&oldid=1978451831"